GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:RO) » Definitions » EV-to-FCF
中文

Roche Holding AG (XSWX:RO) EV-to-FCF : 17.41 (As of Apr. 24, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Roche Holding AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Roche Holding AG's Enterprise Value is CHF199,233 Mil. Roche Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF11,446 Mil. Therefore, Roche Holding AG's EV-to-FCF for today is 17.41.

The historical rank and industry rank for Roche Holding AG's EV-to-FCF or its related term are showing as below:

XSWX:RO' s EV-to-FCF Range Over the Past 10 Years
Min: 13.62   Med: 18.43   Max: 28.15
Current: 17.39

During the past 13 years, the highest EV-to-FCF of Roche Holding AG was 28.15. The lowest was 13.62. And the median was 18.43.

XSWX:RO's EV-to-FCF is ranked better than
59.84% of 508 companies
in the Drug Manufacturers industry
Industry Median: 21.86 vs XSWX:RO: 17.39

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-24), Roche Holding AG's stock price is CHF250.20. Roche Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF14.310. Therefore, Roche Holding AG's PE Ratio for today is 17.48.


Roche Holding AG EV-to-FCF Historical Data

The historical data trend for Roche Holding AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG EV-to-FCF Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.76 22.75 19.89 19.09 19.15

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.89 - 19.09 - 19.15

Competitive Comparison of Roche Holding AG's EV-to-FCF

For the Drug Manufacturers - General subindustry, Roche Holding AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's EV-to-FCF falls into.



Roche Holding AG EV-to-FCF Calculation

Roche Holding AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=199232.907/11446
=17.41

Roche Holding AG's current Enterprise Value is CHF199,233 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF11,446 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG  (XSWX:RO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Roche Holding AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=250.20/14.310
=17.48

Roche Holding AG's share price for today is CHF250.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF14.310.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Roche Holding AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (XSWX:RO) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (XSWX:RO) Headlines

No Headlines